Why does a biologic my clinician already prescribed need separate approval?
Most plans require prior authorization before covering a biologic. Many also require step therapy: trying and failing a cheaper treatment first, even if your clinician already believes the biologic is the right choice. I read a 2019 survey that found 41% of people with psoriatic disease had gone through step therapy. Evidence
Why this matters
- Sources cited, not yet graded
Step therapy is common enough that more than 25 states have passed laws requiring plans to offer a way to request an exception. People I have heard from ask what prior authorization involves, and what it will cost them, before almost anything else.
Considerations
- Depends on you
Whether step therapy applies to you depends on your exact plan, not on psoriasis severity alone. A state exception law may not reach a self-funded employer plan, since federal law usually governs those instead.
Questions for your plan or specialty pharmacy
Does this plan require step therapy for this biologic, and what exactly counts as "failing" the prior treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Is this plan state-regulated or self-funded?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
From prescription to a plan decision
Your clinician prescribes it
The biologic is chosen in the clinic, before any plan has looked at the request.
Prior authorization
Most plans review the request themselves before they agree to pay for a biologic.
Step therapy
Many plans require a cheaper option to fail first, which 41% of people surveyed had gone through.
Exception request
More than 25 states require plans to offer a way to ask for an exception to that rule.
Plan stages from the National Psoriasis Foundation, State Advocacy.
My clinician says I need this exact biologic now. Can that requirement be skipped?
Sometimes. Many state step-therapy laws require plans to offer a formal exception-request process. It is usually built around your clinician documenting why the required first-line option is unsuitable for you. Evidence
Why this matters
- Sources cited, not yet graded
Advocacy groups track this as a live policy area precisely because plans do not volunteer the exception process; you usually have to ask for it by name.
Considerations
- Depends on you
The exact form, required documentation, and turnaround time vary by state and plan, and some plans and jurisdictions have no such process at all. I cannot tell you which rule applies to your plan.
Questions for your plan or specialty pharmacy
Does this plan have a step-therapy exception process, and what does my clinician need to submit?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What is the deadline for a decision once the exception request is submitted?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
A copay card made this affordable, then my cost jumped later in the year. What happened?
Some health plans run a copay accumulator adjustment program (CAAP): a rule that stops manufacturer copay-card money from counting toward your deductible or out-of-pocket maximum. The card still lowers what you pay at the pharmacy. But your deductible resets as if that money was never applied, so a cost that looked covered can reappear later in the year. Evidence
Why this matters
- Sources cited, not yet graded
I read a 2020 survey that found 80% of people with commercial insurance who use a biologic rely on manufacturer copay assistance to afford it. The foundation that ran the survey describes accumulator programs as becoming more common.
Considerations
- Depends on you
Not every plan runs a copay accumulator or maximizer program, and whether yours does is not stated here. Some states restrict the practice; whether that protection reaches your plan depends on the same state-versus-self-funded distinction as step therapy.
Questions for your plan or specialty pharmacy
Does this plan use a copay accumulator or maximizer program?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Where in the plan documents is that program described in writing?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is there a catch to the copay card, or to the groups fighting to protect it?
The savings are real for most people who use them. The same manufacturers who fund copay-card programs also sell the biologics they apply to. Patient-advocacy groups publishing statistics like these often accept funding from those manufacturers, and lobby against both step therapy and accumulator programs. Evidence Evidence
Why this matters
- Sources cited, not yet graded
That funding relationship does not make the 80%-reliance figure or the accumulator mechanism untrue. I would still use a copay card if it lowers your cost now.
Considerations
- Depends on you
It does mean the loudest voices on this topic have a financial stake in more biologic use and fewer coverage restrictions. That is a reason to verify a plan's exact rule yourself, rather than take any single source's framing as the full picture.
Questions for your plan or specialty pharmacy
Where can I read this plan's own copay-accumulator or maximizer policy, in writing, rather than a summary of it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Psoriasis Foundation names its corporate members on its own site (psoriasis.org/corporate-members/, checked 2026-09-09). They include AbbVie, Johnson & Johnson, Leo Pharma, Lilly, Novartis, UCB, Amgen, Sun Pharma, Arcutis, Bristol Myers Squibb, Takeda, and Alumis. Several of those firms make the drugs step therapy and copay-card rules affect. NPF also lobbies against both practices. This number and its framing come from a group with a stake in the fight, even though NPF says it does not back one drug over another.
What this source supports
Supports that a 2019 NPF patient survey found 41% of people with psoriatic disease had gone through step therapy. Supports that, by NPF's own count, more than 25 states have passed a step-therapy law. That law gives a patient a way to ask for an exception. Also supports that NPF wants that same process in every state.
What it does not support
Does not give the survey's size or its margin of error. Does not say which state laws name psoriasis drugs by name. Does not say if a given plan falls under state law at all; a plan an employer funds itself usually does not. The page shows no post or update date. The date used here is the newest state law it names: a Wisconsin law from July 2020. The page itself may be newer. The state count may be out of date too. Does not guess what any one plan will require.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Psoriasis Foundation names its corporate members on its own site (psoriasis.org/corporate-members/, checked 2026-09-09). They include AbbVie, Johnson & Johnson, Leo Pharma, Lilly, Novartis, UCB, Amgen, Sun Pharma, Arcutis, Bristol Myers Squibb, Takeda, and Alumis. Several of those firms make the drugs step therapy and copay-card rules affect. NPF also lobbies against both practices. This number and its framing come from a group with a stake in the fight, even though NPF says it does not back one drug over another.
What this source supports
Supports that a 2020 NPF survey found 80% of people with private insurance who use a biologic use a copay card from the drug's maker to pay for it. Supports that a copay accumulator program (CAAP) is a health-plan rule: it does not count that card money toward the deductible or the yearly cap. Also supports that NPF says these programs are becoming more common.
What it does not support
Does not give the survey's size or its margin of error. Does not say if any one plan runs a copay accumulator or maximizer program, or which states limit the practice. The page shows no post or update date; the date used here is the year of the survey it names, so the page itself may be newer. Does not guess what any one person will owe.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.